Jacob Schroeder at Kiplinger wrote about a Medicare initiative that drops the price of GLP-1 weight-loss drugs to $50 for beneficiaries, and the fine print underneath it. I work with a lot of Medicare-age clients, and he asked me how I am advising them.
The first thing I told him is that I treat the program's start date as fact rather than forecast, because clients are already planning around it. The second is the trap in the Part D out-of-pocket cap. Clients assume hitting the cap means their drug costs are done for the year. The cap covers Part D drugs; a GLP-1 accessed through a different pathway may not count toward it, so the math on "my costs are capped" can be wrong.
The bigger risk is plan switching. Switching Part D plans to chase GLP-1 access can quietly wreck coverage on someone's other five prescriptions. The savings on one drug can be more than erased by higher tiers or gaps on the others.
For a client who qualifies both ways, through a covered diagnosis and through the new program, I generally point them toward the covered-diagnosis route for the long-term stability, even if the near-term cost looks less predictable. A $50 price is only a good deal if the rest of the coverage survives it.
Read the full article at Kiplinger →
